Pharmaceutical Pipeline
Yale is committed to advancing healthcare through groundbreaking technologies and discoveries. Explore a diverse array of pioneering projects that span the entire drug development process, from early-stage research to clinical trials. With a focus on addressing critical medical challenges, Yale's Pharmaceutical Pipeline showcases the collective expertise and dedication of our researchers who are aiming to bring tangible solutions to market for patients worldwide.
Device Diagnostic
Preclinical
XPACE-2003
XPACE-2003 is a preclinical-stage prophylactic mRNA vaccine candidate being developed by Xanadu Bio to target human influenza
- Infectious disease
XPACE-1010
XPACE-1010 is a preclinical, nucleic acid-based therapeutic pipeline candidate being developed by Xanadu Bio for the treatment of Non-Small Cell Lung Cancer (NSCLC).
- Oncology
XPACE-1009
XPACE-1009 is a preclinical, nucleic acid-based therapeutic pipeline candidate being developed by Xanadu Bio for the treatment of Non-Small Cell Lung Cancer (NSCLC).
- Oncology
XPACE-1008
AI Overview
XPACE-1008 is an IL-2 modulator drug initially developed by the biotechnology company Xanadu Bio Inc.
XPACE-1007
XPACE-1007 is a preclinical therapeutic candidate from Xanadu Bio aimed at treating Non-Small Cell Lung Cancer (NSCLC). The asset leverages the company's proprietary poly(amine-co-ester) or PACE polymer nanoparticle platform.
- Oncology
XPACE-2005
XPACE-2005 (also referenced alongside alternative candidate designations like XPACE 2004) is a preclinical prophylactic mRNA vaccine candidate developed by Xanadu Bio Inc.. It is designed to target and protect against Respiratory Syncytial Virus (RSV) infections.
- Therapeutics & Vaccines
- Vaccines/Infectious Disease
XPACE-2004
XPACE-2004 (also written as XPACE 2004) is an investigational mRNA prophylactic vaccine developed by Xanadu Bio to protect against Respiratory Syncytial Virus (RSV) infections
- Therapeutics & Vaccines
EGFR-Her2 vaccine
- Therajan
Phase I
ARV-6723
Arvinas dosed the first patient in a Phase 1/2 clinical trial for ARV-6723 on September 28, 2026, marking it as the first-ever HPK1 PROTAC degrader to enter clinical trials in the United States.
ARV-393
ARV-6723 is an investigational, oral PROTAC designed to degrade hematopoietic progenitor kinase 1 (HPK1) in adults with advanced solid tumors, marking Arvinas as the first company to bring an HPK1 PROTAC degrader into clinical trials in the United States.
- Oncology
RIG-101
- RIGImmune
- Oncology
ARV-393
ARV-393 is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) BCL6 degrader developed by Arvinas for the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL).
- Oncology
NRM-823
NRM-823 is a first-in-class, bispecific T-cell engager (TCE) developed by Normunity designed to redirect T cells to recognize and destroy cancer cells in patients with locally advanced or metastatic solid tumors.
Overview and Mechanism
• Target: Binds to a proprietary, highly tumor-specific "Immuno-smart" cell-surface target that is co-opted by cancer cells to drive local immune suppression, while remaining absent in normal systemic tissues.
• Function: Acts as a bridge between endogenous T cells and tumor cells, inducing potent T cell-mediated cytotoxicity.
• Platform Origin: Developed through an ongoing academic-biotech partnership with the Lieping Chen laboratory at the Yale School of Medicine.
- Oncology
BHV-1600
Biohaven initiated first-in-human Phase 1 clinical dosing for BHV-1600 in late 2024 to treat peripartum cardiomyopathy (PPCM).
Mechanism: BHV-1600 is a targeted removal of aberrant protein (TRAP) degrader designed to selectively bind and eliminate pathogenic β₁-adrenergic receptor (β₁AR) autoantibodies.
- Cardiovascular
BCSZ110
- Dynamicure
Phase II
PTX-100
- Prescient
FREE001
FREE001 is an investigational adjunctive combination therapy developed by Freedom Biosciences for the treatment of adults with treatment-resistant depression (TRD).
- Mental Health
- Neuroscience
BHV-1400
BHV-1400 is a first-in-class, antigen-specific TRAP™ extracellular protein degrader developed by Biohaven to treat IgA nephropathy (IgAN).
HLD-0915
Halda Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating HLD-0915 in Metastatic Castration-Resistant Prostate Cancer
First-in-human clinical trial to evaluate safety and tolerability of a new class of small molecule medicines for the treatment of cancer, RIPTAC™ therapeutics
- Oncology
Phase III
BHV-1300
Molecular Degraders of Extracellular Proteins (“MoDE™”) are bispecific molecules that target pathologic circulating proteins and direct them to the liver (or other organ systems) for degradation by the endosomal/lysosomal pathway---a novel, competitive platform with a differentiated profile relative to FcRN inhibitors. Specifically, high circulating levels of antibodies (monoclonal or polyclonal gammopathy) drive conditions such as myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgaris, and many other diseases.
- Discovery Platform
- Inflammatory
- Therapeutics